InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,071.63
(
0.71%
)
US TECH 100
16,954.80
(
-0.17%
)
Dow Jones
38,216.00
(
1.06%
)
Brent Oil
83.53
(
-2.76%
)
Bitcoin
58,499.76
(
-3.49%
)
Post# of 251662
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: JohnWayne post# 210075

Thursday, 03/23/2017 4:56:26 PM

Thursday, March 23, 2017 4:56:26 PM

Post# of 251662

lower dose than for CTLA-4 in other tumor types

NSCLC patients for one, are weaker in terms of comorbidities and more prone to lung tox than melanoma patients so final CTLA-4 dose should be lower.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up